To see all protocols that comply with the WHO Essential Medicine List 

This protocol has been superseded as it is not considered best practice for this patient population. AML Induction 7-3 (cytarabine and DAUNOrubicin) is the preferred regimen.

Patients with leukaemia should be considered for inclusion into clinical trials. Link to ALLG website and ANZCTR website.

There are a number of AML induction 7-3 protocols available on eviQ each of which have subtle differences in doses of the chemotherapy agents. Please check the doses to ensure you are viewing the correct protocol with your intended dosing schedule.

This protocol is not exportable and does not have a calculator.

The original paper was published with a dosage error which stated cytarabine be administered once daily in cycle two. This was amended in 2010 to the correct dose of twice daily cytarabine. Please see Erratum to N Engl J Med. 2009 Sep 24;361(13):1235-48 for details.

The information contained in this protocol is based on the highest level of available evidence and consensus of the eviQ reference committee regarding their views of currently accepted approaches to treatment. Any clinician (medical oncologist, haematologist, radiation oncologist, medical physicist, radiation therapist, pharmacist or nurse) seeking to apply or consult this protocol is expected to use independent clinical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use is subject to eviQ’s disclaimer available at

Send feedback for this page

First approved:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

07 Jul 2020